Harmony Biosciences appoints Dayno as Interim President and CEO; details compensation

Harmony Biosciences Holdings, Inc.

Dr. Jeffrey Dayno appointed Interim President and CEO effective Jan 6, 2023; continues as CMO.
Annual base salary set at $530,000; target annual bonus of 75% of base salary.
One-time cash bonus of $300,000 payable upon earlier of June 30, 2024 or change in control.
Upon permanent CEO appointment, Dayno reverts to EVP/CMO with base salary $530,000 and 75% target bonus.
Executive Chairman Jeffrey Aronin to receive $500,000 annual cash payment, pro-rated quarterly.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Jeffrey S. Aronin

Executive Chairman

HRMY · Harmony Biosciences Holdings, Inc.

Effective: 2023-01-06
Filed: January 23, 2023, 6:59 PM ET

the Board appointed Jeffrey S. Aronin, currently Chairman of the Board, as the Company’s Executive Chairman, effective January 6, 2023.

Departed

John Jacobs

Other

HRMY · Harmony Biosciences Holdings, Inc.

Filed: January 23, 2023, 6:59 PM ET

in connection with Mr. John Jacobs’ resignation from the Company and the Board

Appointed (interim)

Jeffrey M. Dayno

Interim President and Chief Executive Officer

HRMY · Harmony Biosciences Holdings, Inc.

Effective: 2023-01-06
Filed: January 23, 2023, 6:59 PM ET

the Board appointed Dr. Jeffrey M. Dayno as the Company’s Interim President and Chief Executive Officer (“CEO”), effective January 6, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jeffrey S. Aronin was appointed as Executive Chairman at Harmony Biosciences Holdings, Inc..

Action: appointed
Role: Executive Chairman

Exact text from the filing

the Board appointed Jeffrey S. Aronin, currently Chairman of the Board, as the Company’s Executive Chairman, effective January 6, 2023.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.7

John Jacobs resigned as other at Harmony Biosciences Holdings, Inc..

Action: resigned

Exact text from the filing

in connection with Mr. John Jacobs’ resignation from the Company and the Board

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Jeffrey M. Dayno was appointed as Interim President and Chief Executive Officer at Harmony Biosciences Holdings, Inc..

Action: appointed
Role: Interim President and Chief Executive Officer

Exact text from the filing

the Board appointed Dr. Jeffrey M. Dayno as the Company’s Interim President and Chief Executive Officer (“CEO”), effective January 6, 2023.

View on SEC.gov

Harmony Biosciences Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-000424

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.